177 related articles for article (PubMed ID: 35313232)
1. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Lombardi P; Filetti M; Falcone R; Di Bidino R; Iacovelli R; Ciccarese C; Bria E; Tortora G; Scambia G; Daniele G
Cancer Treat Rev; 2022 May; 106():102377. PubMed ID: 35313232
[TBL] [Abstract][Full Text] [Related]
2. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Wang S; Lv H; Yu J; Chen M
Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM
Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482
[TBL] [Abstract][Full Text] [Related]
6. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Hahn AW; Klaassen Z; Agarwal N; Haaland B; Esther J; Ye XY; Wang X; Pal SK; Wallis CJD
Eur Urol Oncol; 2019 Nov; 2(6):708-715. PubMed ID: 31588018
[TBL] [Abstract][Full Text] [Related]
7. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.
Yanagisawa T; Mori K; Matsukawa A; Kawada T; Katayama S; Bekku K; Laukhtina E; Rajwa P; Quhal F; Pradere B; Fukuokaya W; Iwatani K; Murakami M; Bensalah K; Grünwald V; Schmidinger M; Shariat SF; Kimura T
Cancer Immunol Immunother; 2024 Jan; 73(2):38. PubMed ID: 38289361
[TBL] [Abstract][Full Text] [Related]
8. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
Liu Z; Chen Y; Wei Z; He Y; Wang J; Mu X; He L; Li R; Hu X; Peng X
Ann Palliat Med; 2021 Mar; 10(3):2805-2814. PubMed ID: 33615806
[TBL] [Abstract][Full Text] [Related]
10. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma.
Riaz IB; He H; Ryu AJ; Siddiqi R; Naqvi SAA; Yao Y; Husnain M; Narasimhulu DM; Mathew J; Sipra QUAR; Vandvik PO; Joseph RW; Liu H; Wang Z; Herasevich V; Singh P; Hussain SA; Ho TH; Bryce AH; Pagliaro LC; Murad MH; Costello BA
Eur Urol; 2021 Dec; 80(6):712-723. PubMed ID: 33824031
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis.
Quhal F; Mori K; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Curr Opin Urol; 2022 Jan; 32(1):61-68. PubMed ID: 34720102
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis.
Gao Z; Huang S; Wang S; Tang D; Xu W; Zeng R; Qiao G
Lancet Reg Health West Pac; 2023 Sep; 38():100841. PubMed ID: 37457900
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
14. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
Gao TT; Shan JH; Yang YX; Zhang ZW; Liu SL; Xi M; Liu MZ; Zhao L
BMC Cancer; 2022 Sep; 22(1):992. PubMed ID: 36115960
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis.
Liao Y; Hou H; Han Z; Liu Y
Medicine (Baltimore); 2022 Sep; 101(37):e30333. PubMed ID: 36123840
[TBL] [Abstract][Full Text] [Related]
16. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy.
Yanagisawa T; Kawada T; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Chlosta M; Quhal F; Pradere B; Karakiewicz PI; Mori K; Kimura T; Shariat SF; Schmidinger M
BJU Int; 2024 Apr; ():. PubMed ID: 38659099
[TBL] [Abstract][Full Text] [Related]
17. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
18. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
Elaidi R; Phan L; Borchiellini D; Barthelemy P; Ravaud A; Oudard S; Vano Y
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32599839
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
Mori K; Mostafaei H; Miura N; Karakiewicz PI; Luzzago S; Schmidinger M; Bruchbacher A; Pradere B; Egawa S; Shariat SF
Cancer Immunol Immunother; 2021 Feb; 70(2):265-273. PubMed ID: 32757054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
